Riverside portfolio company A.forall has signed a definitive agreement to sell its retail and hospital business unit to Abacus Medicine. Riverside originally invested in A.forall, formerly known as ...
MINNETONKA, Minn.--(BUSINESS WIRE)--A.forall’s U.S. subsidiary Milla Pharmaceuticals Inc. announced the launch of the group’s generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 200 ...
MINNETONKA, Minn.--(BUSINESS WIRE)--Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Acella Pharmaceuticals LLC, has just commercialized its Abbreviated New Drug ...
WHITE BEAR LAKE, Minn., July 23, 2025--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., A.forall announced the direct commercialization and launch of Sodium Acetate Injection ...
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach ANDERLECHT, Belgium, September 09, 2025--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of ...
A.forall, which is backed by The Riverside Company, has acquired Provepharm’s US generics portfolio. No financial terms were disclosed. The deal includes four FDA-approved and marketed sterile ...
“After our rebranding into A.forall, uniting our teams and businesses under one single name that embodies our joint mission of making affordable medicines available to all, this fourth U.S. launch is ...
ANDERLECHT, Belgium--(BUSINESS WIRE)--#FocusToGrow--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results